New drug demonstrates favorable toxicity profile and efficacy in previously treated non-small cell lung cancer patients

August 2003
PharmaWatch: Cancer;August 2003, Vol. 2 Issue 8, p17
Market Research Report
Announces that Allos Therapeutics has published results from a clinical study conducted by researchers at the Memorial Sloan-Kettering Cancer Center on PDX as treatment for non-small cell lung cancer. Response rate and symptomatic benefit from the drug.


Related Articles

  • Xyotax receives FDA 'fast track' designation for lung cancer.  // PharmaWatch: Cancer;August 2003, Vol. 2 Issue 8, p17 

    Highlights the fast-track designation received by Cell Therapeutics from the U.S. Food and Drug Administration for the treatment of advanced non-small cell lung cancer. Reasons for granting the status.

  • Schering-Plough loses momentum on anticancer drug, but set to bounce back. Mirasol, Feliza // Chemical Market Reporter;2/16/2004, Vol. 265 Issue 7, p9 

    Reports on pharmaceutical firm Schering-Plough Corp.'s termination of clinical trials of its anticancer drug Sarasar for non-small-cell lung cancer. Reasons of the company for discontinuing trials; Impact of the setback on the company's business outlook.

  • Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Bennouna, J.; Breton, J.-L.; Tourani, J.-M.; Ottensmeier, C.; O'Brien, M.; Kosmidis, P.; Huat, T. E.; Pinel, M.-C.; Colin, C.; Douillard, J.-Y. // British Journal of Cancer;5/22/2006, Vol. 94 Issue 10, p1383 

    A multicentre, single-arm, phase II trial designed to determine the efficacy of single-agent vinflunine in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum-based regimen. The objectives were to assess efficacy in terms of tumour response rate (primary...

  • Erlotinib prolongs survival of patients with NSCLC.  // Formulary;Nov2004, Vol. 39 Issue 11, p529 

    Reports on a study evaluating the use of the investigational agent erlotinib to treat non-small-cell lung cancer. Survival rates; Safety profile; Treatment outcomes.

  • Other Cancer News Headlines January 15, 2004--February 14, 2004.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p20 

    Presents news update on drug developments targeting various cancers, compiled as of February 14, 2004. NeoPharm's agreement with Food and Drug Administration (FDA) on phase III trial for its experimental anticancer drug; Plan of FDA to review Allos' application for a brain cancer drug;...

  • Gefitinib approved for lung cancer.  // WHO Drug Information;2003, Vol. 17 Issue 2, p102 

    Reports that the U.S. Food and Drug Administration (FDA) has announced the approval of gefitinib tablets as a single agent treatment for patients with advanced non small-cell lung cancer. Approval of gefitinib as a treatment for patients whose cancer has continued to progress despite treatment...

  • Pemetrexed/carboplatin for NSCLC: QOL impact assessed.  // PharmacoEconomics & Outcomes News;6/27/2009, Issue 581, p8 

    The article discusses research on the impact of the use of pemetrexed plus carboplatin as a first-line therapy for non-small-cell lung cancer (NSLC) on the quality of life of patients. It references a study by R. M. Bremnes and colleagues published in the May 11, 2009 issue of the "Journal of...

  • Cell Therapeutics to advance polyglutamate camptothecin to phase II clinical trials.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p12 

    Reports on the announcement of Cell Therapeutics of its plan to begin phase I and II studies of its novel camptothecin polymer conjugate in combination with standard chemotherapy in colorectal cancer and as a single agent in small cell lung cancer, in 2004. Recognition of camptothecin as one of...

  • Erratum.  // JNCI: Journal of the National Cancer Institute;Jan2012, Vol. 104 Issue 1, p79 

    A correction to the article "Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410" that was published in a 2011 issue is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics